Live feed08:00:00·1722dPRReleasevia QuantisnowRedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 PatientsByQuantisnow·Wall Street's wire, on your screen.RDHL· Redhill Biopharma Ltd.Health Care
